|Description||Healthcare investment company|
Mérieux Développement is the healthcare investment company of Institut Mérieux, a French industrial holding company dedicated to biology, which currently employs more than 10,000 people worldwide. Institut Mérieux has majority ownership of bioMérieux (NYSE Euronext, BIM), Silliker, Transgene (NYSE Euronext, TNG) and ABL Inc. Mérieux Développement intends to invest up to €70 million as minority shareholder from 2010 to 2013 in the field of healthcare on a global basis, working alongside entrepreneurs and innovative companies whose products and services can bring genuine advances to the health of patients and consumers worldwide.
|Kalila Medical||4/2014||Venture Round||1|
|NeuroPhage Pharmaceuticals||3/2014||Series D||$17M||2|
|NeuroPhage Pharmaceuticals||5/2013||Series C||$6.4M||2|
|NeuroPhage Pharmaceuticals||3/2012||Series B||$9M||2|
|NeuroPhage Pharmaceuticals||3/2011||Series B||$12.4M||2|